ZA200800180B - Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative - Google Patents
Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivativeInfo
- Publication number
- ZA200800180B ZA200800180B ZA200800180A ZA200800180A ZA200800180B ZA 200800180 B ZA200800180 B ZA 200800180B ZA 200800180 A ZA200800180 A ZA 200800180A ZA 200800180 A ZA200800180 A ZA 200800180A ZA 200800180 B ZA200800180 B ZA 200800180B
- Authority
- ZA
- South Africa
- Prior art keywords
- prevention
- treatment
- liver diseases
- pyrazolopyrimidine derivative
- present
- Prior art date
Links
- 208000019423 liver disease Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical class N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 title 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 abstract 4
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 2
- 208000007232 portal hypertension Diseases 0.000 abstract 2
- 210000003240 portal vein Anatomy 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000004024 hepatic stellate cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050050033 | 2005-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200800180B true ZA200800180B (en) | 2009-01-28 |
Family
ID=37498629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200800180A ZA200800180B (en) | 2005-06-10 | 2008-01-08 | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8796286B2 (da) |
| EP (1) | EP1888074B1 (da) |
| JP (1) | JP4879977B2 (da) |
| KR (1) | KR100914445B1 (da) |
| CN (1) | CN101193636B (da) |
| AT (1) | ATE537832T1 (da) |
| AU (1) | AU2005332719B2 (da) |
| BR (1) | BRPI0520209A2 (da) |
| CA (1) | CA2611638C (da) |
| CY (1) | CY1112637T1 (da) |
| DK (1) | DK1888074T3 (da) |
| ES (1) | ES2376628T3 (da) |
| HK (1) | HK1119596A1 (da) |
| IL (1) | IL187678A (da) |
| MX (1) | MX2007015365A (da) |
| NO (1) | NO20076053L (da) |
| NZ (1) | NZ564369A (da) |
| PT (1) | PT1888074E (da) |
| RU (1) | RU2369392C2 (da) |
| UA (1) | UA86528C2 (da) |
| WO (1) | WO2006132460A1 (da) |
| ZA (1) | ZA200800180B (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100322917A1 (en) * | 2006-12-28 | 2010-12-23 | Insect Biotech Co., Ltd. | Pharmaceutical composition containing arazyme for the prevention of liver dysfunction |
| WO2010118367A2 (en) * | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| KR20130026504A (ko) * | 2010-07-14 | 2013-03-13 | 큠버랜드 에멀징 테크놀로지스 아이앤씨 | 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법 |
| EP2873017B1 (en) | 2012-07-11 | 2021-09-01 | University of Mississippi Medical Center | Method for the detection and staging of liver fibrosis from image acquired data |
| ES2848348T3 (es) | 2014-05-16 | 2021-08-06 | Cumberland Pharmaceuticals Inc | Composiciones y métodos de tratamiento con ifetroban de la fibrosis cardíaca |
| KR102448406B1 (ko) | 2015-06-30 | 2022-09-27 | 큠버랜드 파마슈티컬즈 인코포레이티드 | Ａｅｒｄ/천식에서 트롬복산 수용체 길항제 |
| AU2017263462B2 (en) | 2016-05-11 | 2021-05-13 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists |
| CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
| CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
| CA3229274A1 (en) * | 2021-08-13 | 2023-02-16 | Mezzion Pharma Co., Ltd. | Methods and compositions for treating fibrotic liver conditions, using udenafil compositions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100353014B1 (ko) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
| KR100377782B1 (ko) | 2000-06-23 | 2003-03-29 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법 |
| US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| GB0202254D0 (en) | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| GB0214784D0 (en) | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
| WO2004037183A2 (en) | 2002-10-22 | 2004-05-06 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
| WO2004108662A1 (ja) | 2003-05-15 | 2004-12-16 | Kumiai Chemical Industry Co., Ltd. | フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤 |
| DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
| JP2006527257A (ja) * | 2003-06-10 | 2006-11-30 | ファイザー・インク | 月経困難症の治療用のｐｄｅ阻害剤及びバソプレッシン受容体アンタゴニストを含んでなる療法組合せ |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
-
2005
- 2005-10-21 RU RU2007149474/15A patent/RU2369392C2/ru active
- 2005-10-21 KR KR1020050099900A patent/KR100914445B1/ko active IP Right Grant
- 2005-10-21 AU AU2005332719A patent/AU2005332719B2/en not_active Ceased
- 2005-10-21 DK DK05808627.3T patent/DK1888074T3/da active
- 2005-10-21 ES ES05808627T patent/ES2376628T3/es active Active
- 2005-10-21 JP JP2008515614A patent/JP4879977B2/ja not_active Expired - Fee Related
- 2005-10-21 CA CA2611638A patent/CA2611638C/en not_active Expired - Fee Related
- 2005-10-21 UA UAA200713931A patent/UA86528C2/uk unknown
- 2005-10-21 WO PCT/KR2005/003526 patent/WO2006132460A1/en active Application Filing
- 2005-10-21 CN CN2005800500656A patent/CN101193636B/zh not_active Expired - Fee Related
- 2005-10-21 MX MX2007015365A patent/MX2007015365A/es active IP Right Grant
- 2005-10-21 BR BRPI0520209-4A patent/BRPI0520209A2/pt not_active IP Right Cessation
- 2005-10-21 US US11/916,752 patent/US8796286B2/en active Active
- 2005-10-21 PT PT05808627T patent/PT1888074E/pt unknown
- 2005-10-21 NZ NZ564369A patent/NZ564369A/en not_active IP Right Cessation
- 2005-10-21 EP EP05808627A patent/EP1888074B1/en active Active
- 2005-10-21 AT AT05808627T patent/ATE537832T1/de active
-
2007
- 2007-11-26 NO NO20076053A patent/NO20076053L/no not_active Application Discontinuation
- 2007-11-27 IL IL187678A patent/IL187678A/en not_active IP Right Cessation
-
2008
- 2008-01-08 ZA ZA200800180A patent/ZA200800180B/xx unknown
- 2008-11-27 HK HK08112976.5A patent/HK1119596A1/xx not_active IP Right Cessation
-
2012
- 2012-03-14 CY CY20121100272T patent/CY1112637T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2611638A1 (en) | 2006-12-14 |
| JP2008543748A (ja) | 2008-12-04 |
| IL187678A (en) | 2013-04-30 |
| EP1888074A4 (en) | 2010-06-23 |
| KR100914445B1 (ko) | 2009-08-28 |
| RU2369392C2 (ru) | 2009-10-10 |
| RU2007149474A (ru) | 2009-07-20 |
| KR20060128605A (ko) | 2006-12-14 |
| NO20076053L (no) | 2008-02-27 |
| JP4879977B2 (ja) | 2012-02-22 |
| WO2006132460A1 (en) | 2006-12-14 |
| IL187678A0 (en) | 2008-11-03 |
| AU2005332719A1 (en) | 2006-12-14 |
| HK1119596A1 (en) | 2009-03-13 |
| EP1888074B1 (en) | 2011-12-21 |
| AU2005332719B2 (en) | 2010-05-13 |
| PT1888074E (pt) | 2012-03-01 |
| EP1888074A1 (en) | 2008-02-20 |
| CY1112637T1 (el) | 2016-02-10 |
| MX2007015365A (es) | 2008-02-12 |
| ATE537832T1 (de) | 2012-01-15 |
| US20080207646A1 (en) | 2008-08-28 |
| CN101193636A (zh) | 2008-06-04 |
| DK1888074T3 (da) | 2012-01-23 |
| UA86528C2 (uk) | 2009-04-27 |
| CA2611638C (en) | 2010-08-24 |
| US8796286B2 (en) | 2014-08-05 |
| BRPI0520209A2 (pt) | 2009-04-22 |
| CN101193636B (zh) | 2011-12-28 |
| NZ564369A (en) | 2010-03-26 |
| ES2376628T3 (es) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1119596A1 (en) | Use of yrazolopyrimidinone derivative in the preparation of agent for the prevention and treatment of liver diseases | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
| TW200609227A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| NO20075136L (no) | Nye liposompreparater | |
| MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
| WO2008039218A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
| WO2005075471A3 (en) | Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| WO2007056236A3 (en) | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| WO2005065429A3 (en) | Composition and method for treatment of hepatic encephalopathy | |
| RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| IL191670A0 (en) | Compounds for the inhibition of apoptosis | |
| TNSN06072A1 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
| JO2492B1 (en) | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients | |
| MY148300A (en) | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative | |
| WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption |